Thus, interactions between AR signaling and GR-mediated transcriptional changes are likely involved in the therapeutic efficacy of combination treatment using β2AR and GR agonists for asthma and COPD. This evidence concerns the gene NR3C1 and chronic obstructive pulmonary disease.